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MEANS TO ACHIEVE SUSTAINED RELEASE
OF SYNERGISTIC DRUGS BY

as a prodrug Where the carboxy-protecting group can be

readily cleaved in vivo. These carboxy protecting groups are
indicated to be used in the protection of carboxyl groups in

CONJUGATION

penicillin and cephalosporin.
US. Pat. No. 4,489,065 to Walton et al., discloses chon

This application is a continuation of US. Ser. No.

droitin drug complexes. The ’065 patent describes that the

08/388,855, ?led Feb. 15, 1995, abandoned, Which is a
continuation-in-part of US. Ser. No. 08/187,462, ?led Jan.
28, 1994.
TECHNICAL FIELD

rate of drug release can be controlled in a variety of Ways,
such as by encapsulation in a material Which dissolves
10

a so called “prodrug”, in Which the drug is bound With
another substance turning it into a substantially inactive

The present invention is related to the ?eld of controlled

pharmaceutical delivery, Especially to codrug compounds.

compound or complex. The drug is gradually released by

BACKGROUND ART

Aprodrug is a compound formed by chemical modi?ca
tion of a biologically active compound Which Will liberate

physiological action When injected into the tissues of the
15

the active compound in vivo by enZymatic or hydrolytic
cleavage. The primary purpose of employing a prodrug for
oral administration is to increase intestinal absorption or site
speci?c absorption or to reduce local side effects, such as

gastrointestinal irritation. Prodrugs may also be used to

patient. The ’065 patent discloses chondroitin or chondroitin
sulphate covalently or ionically bonded to a drug substance

of the group consisting of chloramphenicol, methotrexate,

20

adriamycin, vinblastine, vincristine, vindesine,
6-mercaptopurine, 5-?uorouracil, penicillin antibiotics,
cephalosporin antibiotics, and oxacephalosporin antibiotics,
to form a prodrug. The patent states that the prodrug
provides controlled release of the drug in a physiological
environment. The patent discloses that a variety of func

increase transdermal absorption, by enhancing permeation
through topical membranes.

tional groups are available in chondroitan for covalently

On this basis, prodrugs are not generally classi?ed as

sustained release dosage forms. HoWever, the ability to
bioreversibly modify the physicochemical properties of a
drug alloWs better intestinal transport properties and hence

sloWly in the body ?uids, by entrapment in a bolus or matrix
from Which the drug diffuses sloWly, or by conversion into

25

bonding (particularly carboxyl, COOH, and hydroxyl, OH)
and for ionic bonding (sulfate —OSO3—, and carboxylate,
—COO—) With drugs. Covalent bonding can be by Way of

can in?uence the drug blood levels versus time pro?le of the

Which include polymers Which are biodegradable because of

ester links, —COOY, or amide links, —CONHY—. When
chondroitin and the drug substance contain a hydroxyl and
an amino group, the reaction can proceed through the
formation of a carbamate bond via activation of the hydroxyl
to a chloroformate moiety With subsequent linking to the
amine function. The rate of release of the drug from the
chondroitin or from the linking substance is dependent on
the type of bonds chosen for linkage.

the hydrolyZable phosphoester or P—(O)—O—C bond. A
particular aspect of the Leong patent is a therapeutic agent

polymer-drug conjugate and a method of producing it.

pharmaceutical compound. Thus, prodrugs can be used to
increase the strategies for sustained release and, in a limited
sense, can be sustaining in their oWn right.
US. Pat. No. 5,176,907 to Leong et al. discloses biocom

30

patible and biodegradable poly(phosphoester-urethanes).
The patent describes therapeutic agent delivery vehicles

US. Pat. No. 5,130,126 to Koyama et al. discloses a

that can be .Introduced into the poly-phosphoester urethane

by covalently binding a radical of this therapeutic agent to
the phosphorous atom of the polymer. The patent describes
attaching 5-?uorouracil to polyurethane. The patent dis
closes that drugs With carboxyl groups can be coupled to the

Polymers Which may be used have an alkyleneoxy group as
a repeating unit such as polyoxyalkylene glycol as Well as
40

combined With drugs using covalent bonding, ionic bonding,
coordinate bonding, and shiff base formation.

phosphorous atom via an ester bond Which is hydrolyZable.
US. Pat. No. 5,194,581 to Leong et al. discloses biode

gradable polyphosphoesters. A therapeutic agent is pen

polymers obtained by substituting the terminal groups of the
polymers With an acyl, amino or allyl group. Polymers are

45

US. Pat. No. 5,057,301 to Wilbur et al. discloses modi?ed
cellular substrates used as linkers for increased cell retention

dently bound to a poly(phosphoester) polymeric matrix.
When the therapeutic agent is pendently attached, it is
chemically linked through, for example, ionic or covalent
bonding. The drug is released When the polymeric agent

of diagnostic and therapeutic agents. The invention of Wil
bur et al. comprises a ligand-linker conjugate Wherein the

biodegrades. A combination of one or more therapeutic

conjugation group attached to the modi?ed substrate linker

agents can be incorporated into the composition of the
invention. The patent discloses therapeutic agents contain
ing tWo hydroxyl groups that can be directly incorporated
into the backbone of the polymers. Other therapeutic agents

is a functional group Which Will react With the group on the

can be derivatiZed for incorporation into the backbone. For
instance, a drug With tWo amino groups can be reacted With

linker is a chemically modi?ed cellular substrate having a

protein conjugation group attached thereto. The protein
targeting protein and form a bond betWeen the linker and the

55

protein. Suitable protein conjugation groups include active
esters (including carboxylic esters, imide esters, succinim
idyl esters, phenolic esters, and imidate esters), primary or

secondary amines, hydraZides, hydraZines, carboxylate,

the carboxyl group of a hydroxyl carboxylic acid. The
hydroxyl groups can then be used to form the poly

isothiocyanates, isocyanates, and Michael-type acceptor

(phosphoester). A sustained delivery is effected by the

halides.

hydrolysis of the polymeric prodrug. Although Leong dis

groups such as maleimides, thiols, anhydrides and alkyl
60

US. Pat. No. 5,171,566 to MiZushima et al. discloses a

closes that tWo therapeutic agents may be bound to a

?urbiprofen derivative ophthalmic preparation. The deriva

polymer matrix via covalent bonding, he does not disclose

tive is an ester of ?urbiprofen. US. Pat. No. 4,933,324 to
Shashoua is directed to a fatty acid-neuroactive drug con
jugate used as a prodrug and involves the formation of a
prodrug from a fatty acid carrier and a neuroactive drug. The
bond betWeen the fatty acid and the drug may be an amide

or suggest that tWo therapeutic agents can be linked to one

another by covalent bonding as a prodrug as in the present
invention.
US. Pat. No. 5,104,877 to Boger discloses a psoriasis
treatment. Boger describes a carboxy-protecting group used

65

or an ester bond. US. Pat. No. 4,975,278 to Senter et al.

6,051,576
3

4

discloses antibody-enZyme conjugates in combination With
prodrugs for the delivery of cytotoxic agents to tumor cells.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shoWs a typical release mechanism. Amongst the

US. Pat. No. 4,267,326 to OZaki et al. discloses uracil

advantages of these systems are that as no polymers are
required to control release so the devices can be extremely

derivatives. The uracil derivatives are prepared by reacting
5-?uorouracil With an ot-haloalkyl carboxylate or an alde

small (small enough to be ?tted onto a haptic of an intraocu

hyde diacylate.

lar lens) (IOLs).

US. Pat. No. 4,897,260 to Ross et al. discloses glucocor
ticoid carboxylic acid esters Which include triamcinolone
acetonide 21-oic methylester for the treatment of xeroderma

pigmentosum.

FIG. 2 shoWs devices Were implanted subconjunctivally
in each eye of ten rabbits.
10

US. Pat. No. 4,910,192 to Avery et al. discloses topically
active steroidal anti-in?ammatory agents. The agents are
12-[3 substituted glucocorticoids Wherein the 12 substituent
is a hydroxyl group or a lipophilic group attached to a

12-[3-hydroxyl group. The lipophilic group may be selected
from an alkyl or aryl substituted ester, an ester, a carbamate
and a carbonate groups. The 12th substituent can be a loWer

15

Implants Were immersed in 5 ml of phosphate buffer (pH
7.4) and samples periodically removed for HPLC assay to
20

determine the release of both 5FU and TRI. Implants Were
then inserted into the vitreous of 14 NeW Zealand White
rabbits.
FIG. 5 shoWs that codrug formulations may be used in the

25

joint.

midine nucleoside derivatives for use as antiviral agents.

Chemical Abstracts, Volume 117(8), abstract no. 76315(m)
discloses the stereoselective enZymatic hydrolysis of various
ester prodrugs of ibuprofen and ?urbiprofen.
Chemical Abstracts, Volume 116(18), abstract no. 181046

and 0.5 mg 5-?uoroaracil (5FU) Were small enough to be
?xed to the haptics of IOLs.
FIG. 4 shoWs bioerodible codrug implants Were prepared
1.5 mm in diameter and attached to 6-0 nylon suture.

carboxylic acid ester of a 12-[3-hydroxy group.

US. Pat. No. 5,177,064 to Bodor discloses targeted drug
delivery via phosphonate derivatives. US. Pat. No. 5,112,
835 to Miyasaka et al. discloses 6-substituted acyclopyri

FIG. 3 shoWs codrug devices are entirely composed of
drug and do not require release rate controlling polymers
enabling extremely small systems to be prepared. 1.5 mm
pellets containing 1.5 mg of triamcinolone acetonide (TRI)

treatment of arthritic conditions by injection into the affected

(b) describes the preparation of prodrugs of ?urbiprofen, its

DISCLOSURE OF THE INVENTION

1,2-ethanediol ester and 1,4-butanediol ester. The prodrugs

shoWed high stability in simulated gastric ?uid, simulated
intestinal ?uid and simulated pancreatic ?uid. The drugs
shoWed less toxicity and increased anti-in?ammatory and

An object of the invention provides sustained release
30

analgesic effects.

pounds. The drug compounds may be the same or different.

Also provided for is a codrug composition, comprising at
least tWo drug compounds covalently linked to one another
via a labile bond to form a single codrug composition.

None of the above patents disclose or suggest prodrug
conjugates of tWo or more of the same or different drugs

linked to one another. Nor do they disclose codrug conju
gates Which are linked by reversible covalent bonds, such as

delivery of tWo or more pharmacologically active com

35

Also provided for is a codrug composition Wherein drug
compounds may be linked by labile bonds to another entity

ester, carbamate and carbonate bonds, so that at the desired
site in the body they are cleaved to regenerate the active

such as polyethylene glycol, glycerol or a sugar.

forms of each of the drugs.

least one or more of the drug compounds is selected from the

Patient compliance in consumption of pharmaceutical

An object of the invention providers a codrug Wherein at
40

compositions as part of a therapeutic regimen is critical for
patient recovery and treatment. This is especially critical in
elderly patients Who may have poor memory and Who

exhibit poor patient compliance With a therapeutic regimen
of doses of pharmaceutical compositions. Other high risk
compliance groups include drug addicts, alcoholics and
those requiring long term therapy, for example tuberculosis

pharmacological activity.
The invention provides a codrug composition in solid
form, a codrug composition Which is applied topically for
45

examples in a form selected from the group consisting of a

transdermal patch, ointment, cream, suspension, liquid and

eyedrop.

patients.

A codrug according to the invention may be administered
by a method selected from the group consisting of injection,
inhalation, implantation, applied nasally such as a nasal

Furthermore, knoWn erodible, implantable pharmaceuti
cal substances such as polylactic acid and polyurethane
compounds are formulated such that it is di?icult to achieve

spray, applied rectally, ingested orally and applied vaginally.

high drug loading and hence difficult to deliver large doses
of drug from the substrate. Such drug substances have loW

Another embodiment of the invention provides a codrug
composition attached to a surgically implantable device, for

solubility.
There is a need in the pharmaceutical arts for pharma

group consisting of an antiviral compound, a beta-blocker,
an antibacterial compound, and a biological compound With

55

ceutical compounds Which deliver tWo or more drugs at a

single time in a single dose, Which exhibit controlled drug

example, a codrug attached to a suture. Another embodiment

of the invention provides a codrug composition is in the
form of a nonerodible delivery vehicle Which for example

comprises polyvinyl alcohol.

delivery. In one embodiment, the pharmaceutical com
pounds of the present invention are delivered in a totally

erodible drug delivery device capable of delivering tWo or
more synergistic drugs over a prolonged period. The codrug
compounds of the present invention have the advantage that
linking the tWo drug compounds decreases the solubility of
each through the carbamate, carbonate and ester bonds

60

linking the compounds. The codrug compounds of the

65

The codrug of the invention may comprise from 0.1 to up
to about 100% of said nonerodible delivery vehicle.
Another object of the invention is to provide local deliv
ery of tWo or more synergistic pharmacologic agents or

delivery of tWo or more non-synergistic pharmacologic

agents.

invention have a high degree of chemical or enZymatic

Another object of the invention provides an insoluble
codrug of TRI linked to 5FU. Another object of the invention

lability at physiological pH 7.4.

provides an insoluble codrug of ?urbiprofen (FB) With 5FU.

6,051,576
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Another object of the invention provides an insoluble codrug
of acyclovir (ACV) with EB. Another object of the invention
is to produce an insoluble codrug of an angiostatic steroid,

effect relating to the folloWing areas: treatment of cancerous

primary tumors; chronic pain; tuberculosis; arthritis; rheu
matic conditions; hormonal de?ciencies such as diabetes;

3a,17ot-21-trihydroxy-5[3 pregnane-20-one (THS), With

and modi?cations of the immune response such as in the

5FU. Another object of the invention is to produce an

prevention of transplant rejection and in cancer therapy. A

insoluble codrug of prostaglandin E2 alpha (PGFZot) With
timolol (TM). Another object of the invention provides 5FU

using the codrug compositions of the present invention.

linked to tWo molecules of EB, While another object pro

Such disease states are knoWn to those of ordinary skill in

Wide variety of disease states may be prevented or treated

the art (see Goodman and Gilman, The Pharmacological

vides THS linked to 5FU and PB.

The totally erodible drug delivery device is capable of

10

and The Merck Index, 11th Ed., Merck and Co., Inc.,
RahWay, N]. 1989; incorporated herein by reference in their

delivering tWo or more synergistic drugs over a prolonged

period.
Another object of the invention is to control the release
rate of 5FU and triamcinolone from pellets of 5FU/TRI in a
buffer.
Still another object of the invention is directed to the use

entireties).

In addition, codrug compositions of the present invention

15

cytomegalovirus retinitis, toxoplasmosis, Pneumocystis car
nii and microbacterial avium intracellular.
20

A codrug of the invention may consist of one or more

pharmacologically active compounds in the folloWing

bility of codrug technology as a means to achieve the

classes of agents; anesthetics and pain killing agents such as
lidocaine and related compounds and benZodiaZepain and
related compounds; anticancer agents such as 5 -?uorouracil,

intravitreal delivery of 3a,17ot-21-trihydroxy-5[3 pregnane
20-one (THS), a model angiogenesis inhibiting steroid, and
5FU.

are suitable for treating mammalian organisms infected With
the AIDS virus, manifestations of AIDS such as Kaposi’s
sarcoma, and AIDS related opportunistic infections such as

of codrugs in the inhibition of posterior capsular opaci?ca
tion (PCO) after extracapsular cataract extraction and
intraocular lens implantation.
A further object of the invention investigates the feasi

Basis of Therapeutics, 8th Ed., Pergamon Press, NY, 1990;

25

adriamycin and related compounds; anti-in?ammatory

Another object of the invention provides a totally bio
erodible sustained release system for 5FU and triamcinolone

such as ?uconaZole and related compounds; antiviral com

in the eye.

pounds such as trisodium phophomonoformate,

agents such as 6-mannose phosphate; anti-fungal agents

An additional object of the invention provides a codrug
Which is a salt of amiloride and suramin Which inhibits
angiogenesis and a method of use of this codrug to inhibit

30

tri?uorothymidine, acyclovir, ganciclovir, dideoxyinosine
(ddI), dideoxycytidine (ddC); cell transport/mobility imped
ing agents such as colchicine, vincristine, cytochalsian B
and related compounds; anti-glaucoma drugs such as car

angiogenesis.

bonic anhydrase inhibitors, beta blockers, miotics, cholinest
erase inhibitors, and sympathomimetics; immunological

DESCRIPTION OF THE INVENTION

The present invention provides a means of improving the

35

pharmaceutical and pharmacological properties of pharma
cologically active compounds or prodrugs by conjugating
them together to form a codrug.
Codrugs are formed by conjugation of tWo or more agents
via a labile linkage. Codrug conjugates may be linked via
reversible covalent bonds such as ester, carbonate, cyclic
phosphate ester and carbamate bonds, so that at the required
site in the body they are cleaved to regenerate the active
forms of the drug compounds. Bonds may be, but are not
limited to the type

response modi?ers such as muramyl dipeptide and related

compounds; cytokines and peptides/proteins such as
cyclosporin, insulin, groWth factor or groWth hormones and
steroids. Non steroidal anti-in?ammatory agents include, for

example, ?urbiprofen and indomethacin.
40

45

Codrugs may also be formed of unstable drugs and other
compounds to improve their stability such as levodopa and
the peripheral decarboxylase inhibitor benseraZide.
Codrug formulations may comprise a number of other
substituents to optimiZe release, bioavailability or appear
ance and may be used in sustained release devices or

systems. Such substituents are knoWn to those of ordinary
skill in the art and for example are set forth in Remington ’s

Pharmaceutical Sciences, 18th Ed., Mack Publishing Co.,
Easton, Pa., 1990.
Another embodiment of the p)resent invention comprises
a codrug compound in a nonerodible matrix or reservoir

Wherein Z is O, N, CH2, CHZO or CHZS, Y is O, or N, and

system containing natural or synthetic polymers that are

X is O or S. The rate of cleavage of the tWo drugs can be

biologically compatible With and essentially insoluble in

controlled by the type of bond, the choice of drugs and the
physical form of the conjugate. The bond selected may be
enZyme-speci?c. The bond may be selected from enZymati

body ?uids. Such materials include for example, but are not
55

cally labile bonds, for example, to esterases as in the
ACV-FB linkage, or may be chemically labile (eg. base

catalyZed hydrolysis of the 5FU-TRI linkage). The codrugs
are labile in Water, serum or other bodily ?uids and regen

limited to polyvinyl acetate, polyvinyl alcohol, cross-linked

polyvinyl butyrate, ethylene ethyl acrylate copolymer, poly
ethyl hexyl acrylate, polyvinyl chloride, polyvinyl acetals,
60

erate the active parent drugs. The present invention is the
?rst to combine tWo or more drugs in the form of a codrug

plasticiZed ethylene vinyl acetate copolymer, ethylene vinyl
chloride copolymer, polyvinyl esters, polyvinyl butyrate,
polyvinyl formal, polyamides, polymethyl-methacrylate,
polybutyl methacrylate, plasticiZed polyvinyl chloride, plas
ticiZed nylon, plasticiZed soft nylon, plasticiZed polyethyl

Which generates tWo active drug compounds With improved

ene terethphalate, natural rubber, polyisoprene,

pharmaceutical properties.

polyisobutylene, polybutadiene, polyethylene,
polytetra?uoroethylene, polyvinylidine, chloride,

In an embodiment of the present invention, codrugs have
the applicability of providing a controlled or sustained
release for a systemic or local pharmacologic or physiologic

65

polyacrylonitrile, cross-linked polyvinyl pyrrolidone,
polytri?uorochloroethylene, chlorinated polyethylene, poly

6,051,576
8

7
(1,4,-isopropylidne diphenylene carbonate), vinylidine
chloride, acrylonitrile copolymer, vinyl chloride-diethyl

method under consideration. There are also no concerns of

residual polymer after drug has been released, nor of poly

fumarate copolymer, silicone rubbers (especially medical

mer related toxicity as no polymers are used in the con

grade polydimethylsiloxanes, ethylene-propylene rubber,
silicone-carbonate copolymers, vinylidine chloride-vinyl
chloride copolymer, vinyl chloride-acrylonitrile copolymer

struction of the devices.

Some speci?c examples of codrugs of the invention are

given beloW:

and vinylidine chloride acrylonitrile copolymer.
EXAMPLE 1

In another embodiment, a totally bioerodible sustained
release system for pharmacologically active agents is com

posed of codrug alone (either solid, liquid or colloidal).
Injectable codrug systems have a variety of applications

Codrug from triamcinolone acetonide and bis
10

(hydroxymethyl)-5-?uorouracil (See scheme 1 beloW)
Bis(hydroxylmethyl)-5-?uorouracil (2) (158 mg) Was dis

including, but not limited to arthritis (FIG. 5).

solved in 5 ml. of acetonitrile in an ice bath. To this stirred

The codrug of the invention may be administered in
injectable form selected from the group consisting of

solution 112 ML of triethylamine Was added folloWed by

liposomes, liquids, suspensions and microsphere nanopar

triamcinolone acetonide 21-chloroformate (1) prepared from
15

240 mg of triamcinolone acetonide. The resulting solution
Was stirred at room temperature overnight, concentrated in

ticles. Preparation of such aqueous solutions, liposomes,
emulsion and suspensions are knoWn to those of ordinary

vacuo, redissolved in methylene chloride and Washed With

skill in the art (see Remington’s Pharmaceutical Sciences,
20

Water and brine. The crude product Was chromatographed on
silicagel using chloroform-methanol=100:5 as a solvent
system, 210 mg of solid codrug 17 Was obtained. Yield

25

61.4%; 1H-NMR (CDCl3); 6 0.95 (s,3H C-18), 1.2 (s,3H
C-19), 1.4, 1.55 (2s,6H isopropylidene), 3.25 (m, 1H C-16),
4.4 (m, 1H C-11), 4.8 5.15 (2d, 2H C-21), 5.0 (d, 1H OH),
5.7—5.85 (2d, 2H CHZN), 6.15 (s,1H C-4), 6.35 (d,1H C-2),
7.3 (d,1H C-1), 7.65 (d,1H pyrimidyl H-6), 10.0 (s,1H NH).

18th Ed., Mack Publishing Co., Easton, Pa., 1990, pp.

1504—1712, incorporated herein by reference).
Another embodiment of the invention provides a totally
bioerodible sustained release system for pharmacologically
active agents composed of codrug in a formulation With
another bioerodible substance such as polyvinyl acid,

polyanyhydride, collagen, or polyalkylcyanoacrylates such
as polybutylcyanoacrylate.

EXAMPLE 2

Examples of codrugs of the present invention include
5 -?uorouracil With corticosteroids, acyclovir With ?urbipro
fen and timolol (a beta-blocker) With the prostaglandin
PGF2-alpha. These codrugs are labile When dissolved in
bodily ?uids and are rapidly hydrolyZed to regenerate the
tWo active parent drugs. In the solid form hoWever, they are

Hydrolysis of 5FU/TRI
30

This example measured the chemical and enZymatic
hydrolysis of the 5FU/TRI codrug and determined the
release of drug entities.
A stock solution Was prepared by dissolving 10 mg of

35

series of phosphate buffers at pH 3, 5, 6.4, 7.4 and 8.4 at 37°

stable, even in an aqueous environment because in order to

hydrolyZe they must ?rst be in solution.

Pellets of codrugs of the invention, therefore, sloWly
release drugs in solution or bodily ?uids re?ecting the loW
solubility of the conjugated forms. Pellets may be formu
lated from the codrug compounds alone or With implantable,
bioerodible substances may be selected from polylactic acid

and polyclycolic compounds. Pellets may be formulated by

C. to give ?nal concentrations of 100 ug/ml. Care Was taken
to ensure that these solutions Were indeed solutions and not

40

methods knoWn in the art and may contain 0.1 to about

Was determine in a similar Way using pooled serum from 3

TRI and 5FU/TRI. 5FU Was assayed under different condi
tions.

Codrugs may also be formulated in bioerodible or non
45

(bioerodible) to form a ?lm around, or a matrix With a

HPLC Assays

Samples of buffer containing codrug and hydrolysis prod

codrug to further improve the pharmaceutical properties.
Polylactic acid can be formulated in solutions of 2, 5 and

10% polylactic acid, and has been used to produce 5FU-TRI
codrug pellets attached to sutures. 2% polyvinyl alcohol has
been used to coat pellets of 5FU-THS for subconjunctival

suspensions. Samples Were periodically removed and
assayed by HPLC as described beloW. EnZymatic hydrolysis
volunteers. The assay procedure used distinguished betWeen

100% of the codrug composition.
bioerodible delivery systems to further control their release.
Such bioerodible systems include polylactic acid

5FU/TRI in 10 ml acetonitrile. This Was then added to a

50

ucts Were assayed by HPLC using a fully automated Hitachi
system With a C-18 reverse phase column (25 cm><4 mm><5
pm) and uv detection. The mobile phase Was 40% acetoni
trile buffered to pH 4.0 With 0.02% sodium acetate. The ?oW
rate Was 1.0 ml/min and detection Was at 238 nm. Under

delivery. Polybutyl cyanoacrylate (bioerodible) has been
used to form a matrix With 5FU-TRI pellets attached to an

these conditions the retention time of the codrug 5FU/TRI

intraocular lens haptic and silicone (nonbioerodible) to
attach the same pellets to lens haptic (see Example 7 beloW).

Was 17 minutes While triamcinolone acetonide eluted at 9
55

Furthermore, in one embodiment of the invention a phar

macologically active composition possessing some undesir
able effects may be conjugated to another agent to reduce the
undesirable effects such as isoniaZid With pyroxidine.
Another embodiment of the invention is a codrug formulated

60

minutes. Quantitation limits Were 0.3 and 0.5 ug/ml, respec
tively. Under the above conditions 5FU Was found to elute
With the solvent front and so Was assayed separately. For
5FU an Applied Biosystems HPLC system Was used With a

C-18 reverse phase column (25 cm><4 mm><5 pm) and 0.02%
sodium acetate buffer mobile phase (pH 4.0). The ?oW rate

With other drug or prodrug molecules.
Amongst the advantages of codrug systems are that

Was 1.0 ml/min and detection Was by uv at 266 nm. Under

frequently no polymers are required to control release so that

detection limit 0.2 ug/ml.
Samples of serum Were deproteinated before assay by

the devices can be extremely small (small enough to be ?tted
onto a haptic of an intraocular lens). Codrugs systems can
also be formulated as suspensions (nanoparticle siZe range)
and upper siZe limitations are only imposed the application

these condition the retention time Was 6.5 minutes and the

65

HPLC. 300 pl serum samples Were added to 300 pl aceto
nitrile in a microcentrifuge tube. After vortex mixing for 10
seconds tubes Were centrifuged at 14,000 rpm for 30 min

6,051,576
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nylon suture using intraocular lens grade silicone. Silicone
covered the base of the pellets providing a platform for

utes. To determine the concentration of codrug and steroid
the supernatant Was injected directly onto the HPLC

(sensitivity to 0.6 ug/ml and 1.0 ug/ml, respectively).

suture attachment. Alternatively a solution of 2% or 5%

polylactic acid Was used. Pellets attached by both methods
Were implanted into the vitreous of 8 NeW Zealand White
rabbits through a small incision through the sclera. For each
type of device, tWo animals Were killed after 1, 2, 3, and 4
Weeks and the vitreous and aqueous obtained from the

To quantitate 5FU it Was necessary to remove acetonitrile

before analysis. 300 pl of the supernatant Was dried under
reduced pressure using a speed vacuum. The dried plug Was

then rehydrated With 150 pl deioniZed Water before assay by
HPLC. Interference from serum residues reduced sensitivity
to 1 ug/ml.
The codrug Was hydrolyZed in a ?rst-order process to

froZen sphere. Before death animals Were examined With a
10

Zealand White rabbits in a similar manner to that described,

The rate of hydrolysis Was much faster at high pH and Was

extremely fast in serum (half-life, t1 /2, less than 10 minutes).
15

pH

t/

3.0
5.0
6.4
7.4
8.4
Serum

204
12.7
78
14.1
9.8
8.8

hr
hr
min
min
min
min

This example shoWs that although the 5FU/TRI codrug is
stable in acidic conditions, it is highly labile under physi
ological conditions, breaking doWn to regenerate 5FU and

20

25

except that sclerotomy sites Were smaller in this case (2.5
TWo animals Were sacri?ced after 1, 2, 3 and 4 Weeks
and vitreous and aqueous obtained from the froZen sphere.
HPLC analysis Was then performed on tissue samples and
explanted devices to determine the concentrations of 5FU,
triamcinolone acetonide and intact 5FU/TRI.
No intact codrug Was detected in the vitreous. Mean
intravitreal levels of triamcinolone Were found to be 3.0+/—

0.9 ug/ml. These levels Were maintained for three Weeks,
declining to 0.8+/—0.4 ug/ml on the fourth Week before
dropping beloW the detection limit of the HPLC by Week 5.
This experiment shoWs that sustained levels of TRI and
5FU in the vitreous are achievable by the implantation of a
codrug device. Such a device has the advantages of being

composed entirely of the required drugs and of being

triamcinolone acetonide.
EXAMPLE 3

slit lamp. This platform did not effect release rate (in vitro).
Pellets Were then implanted into the vitreous of 8 NeW

quantitatively generate 5FU and triamcinolone acetonide.

completely bioerodible. No toxic or in?ammatory effects are
30

anticipated as the only compounds being released are 5FU,
triamcinolone acetonide and formaldehyde.

5FU/TRI as a Sustained Release System In Vitro

EXAMPLE 5

This example measures the release rate of 5FU and

triamcinolone from pellets of 5FU/TRI in phosphate buffer.
Pellets (2 mg) of the codrug 5FU/TRI Were prepared in a

5FU-TRI Codrug Implant to Control Scar
Formation in Strabismus Surgery

35

1.5 mm pellet press using a modi?ed Parr Instrument Press.

An in vivo evaluation of scar reduction under 5FU-TRI

Pellets Were then immersed in 5 ml phosphate buffer (pH

implant after extraocular muscle (EOM) surgery in rabbits,

7.4, 37° C.) and 300 pl samples removed each day for 6
days; these Were immediately replaced With 300 pl of buffer.
Samples Were assayed by HPLC for 5FU/TRI, triamcino

an experimental animal model for correlation to human
40

utility.
In each eye of ten rabbits the inferior rectus muscle (IRM)
Was disinserted from the globe and electrocautery Was used

lone acetonide and 5FU. After 6 days, buffer Was completely

replaced, to maintain sink conditions, and sampling contin

to create a scar betWeen the muscle and sclera. After the IRM

ued.
No intact codrug Was detected in the receptor medium by

Was seWn back into its insertion site, four 2 mg codrug
implants Were inserted betWeen sclera and muscle in the
right eye, While the left Was used as a control. Bioerodible
codrug implants releasing 5FU and TRI over 6 Weeks Were

45

HPLC (detection limit 0.5 ug/ml). Release of triamcinolone
acetonide Was found to folloW pseudo Zero order kinetics
With a mean release rate of 1.4+/—0.3 ug/hr. Release of 5FU
Was found to be 0.4+/—0.06 ug/hr.
These rates Were maintained until over 60% of triamci
nolone acetonide and 5FU had been released. The mean ratio

prepared. Devices release equimolar amounts of 5FU and
TRI. Animals Were killed at 1, 2 and 3 Weeks and eyes

eviscerated. Specimens Were prepared and stained With
H&E. The scar thickness and cellular in?ltrate Were deter

mined quantitatively using a Bioscan image analysis pro

of 5FU to triamcinolone acetonide concentration (ug/ml) in
the receptor solution Was 3.40+/—0.15 at all time points, (i.e.,

gram.
Drug treated eyes shoWed an 80% decrease in scar

equimolar release).
This example demonstrates that codrug delivery systems

55

thickness compared to controls (7 to 35 pm). Microscopic
examination of a de?ned area of tissue (40 pmz) revealed a

can be used as sustained release agents hoWever a more

greater number of in?ammatory cells present in the control
tissue (>300 versus <35). The codrug implant may prove

thorough in vivo evaluation must be performed.

useful in scar reduction folloWing EOM surgery.

EXAMPLE 4
60

EXAMPLE 6

5FU/TRI as a Sustained Release System In Vivo

Bioerodible Sustained Release Subconjunctival Co
Delivery of TRI and 5FU

This example measures the release rate and vitreous

concentrations of 5FU and TRI from pellets of 5FU/TRI in
the rabbit vitreous.

Pellets (2 mg) of the codrug 5FU/TRI Were prepared
using a 1.5 mm press. These pellets Were then ?xed onto 6-0

65

This example determined feasibility of a codrug release
system for the subconjunctival co-delivery of 5FU and TRI
for possible use in glaucoma ?ltration surgery.

6,051,576
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Bioerodible codrug implants Were prepared 1.5 mm in
diameter and attached to 6-0 nylon suture. Implants Were

Codrug devices Were prepared as ?at discs 2.5 mm in

diameter Weighing 5 mg. Each device contained approxi

immersed in 5 ml of phosphate buffer (pH 7.4) and samples

mately 3.7 mg of TRI and 1.3 mg of 5FU and Were
composed of over 97% active substance. Devices Were

periodically removed for HPLC assay to determine the
release of both 5FU and TRI. Similar implants Were then
inserted into the vitreous of 14 NeW Zealand White rabbits

implanted subconjunctivally in each eye of ten rabbits (FIG.
2). Toxicity and in?ammation Were determined by Weekly
slit lamp examinations and electroretinograms (ERGs). Ani
mals Were killed after 3, 7, 10 and 14 days and eyes
eviscerated. After freezing at —70° C. devices Were removed
for determination of residual drugs and the complete vitre

(FIG. 4). Toxicity Was assessed by electroretinogram and slit
lamp examination in all animals. Histopathologic examina
tion Was performed on four animals. Ten animals Were used
10

for pharmacokinetics; tWo animals Were killed 1, 2, 3, 4 and
5 Weeks after implantation. Eyes Were enucleated, devices

ous and aqueous dissected from the ice ball to determine the
concentration of 5FU and TRI. TWo animals Were used for

removed and both vitreous and aqueous obtained. All

histology and Were killed 6 Weeks after implantation.
Analysis of explanted devices shoWed 5FU and TRI to

samples Were assayed by HPLC. Five animals received
actual devices in one eye and placebo implants in contralat

have been released at a pseudo Zero order rate of 9 +/—1% 15 eral eyes. These Were killed after 3 and 6 Weeks for

per day over the ?rst ten days. Devices released equimolar

histopathologic examination.

amounts of 5FU and TRI. ERGs Were normal for all animals
and there Was no evidence of toxicity or in?ammation

Devices released TRI at 1.4 ug/hr and 5FU at 0.3 pig/hr in
buffer (equimolar release) and Were Well tolerated in rabbit

around the implantation site.
20

EXAMPLE 7

duration of the pharmacokinetic study.
The delivery system described gives pseudo Zero order

Codrugs in the Prevention of Posterior Capsular

Opaci?cation
This example investigates the use of codrugs in the

25

inhibition of posterior capsular opaci?cation (PCO) after

release of both TRI and 5FU in buffer. As the devices are
small, they can be readily inserted into a normal scleral
MVR blade incision. The devices appear to be Well tolerated

and maintain high, potentially therapeutic, drug levels in the

extracapsular cataract extraction and intraocular lens

vitreous. Levels of TRI and 5FU in the aqueous Were too loW
to be detected. Future Work Will evaluate the use of this

implantation in the rabbit.
Codrug pellets Were prepared that gave pseudo Zero order
release of 5FU and TRI in an equimolar ratio over 6 Weeks.

eyes With no indication of toxicity or in?ammation. Vitreous
levels of TRI Were maintained at 2.4 pig/ml over the 5 Weeks

codrug system in a PVR model.
30

Codrug devices are entirely composed of drug and do not

EXAMPLE 9

require release rate controlling polymers enabling extremely
Intravitreal Delivery of an Anti-Neovascular Agent
and an Antiproliferative Agent in the Rabbit Eye

small systems to be prepared. 1.5 mm pellets containing 1.5
mg of TRI and 0.5 mg 5FU Were prepared and ?xed to the

haptics of IOLs using the bioerodible polybutyl cyanoacry
late. This polymer is soaked into the pellet forming a
codrug/cyanoacrylate matrix as it dried (FIG. 3). 16 NeW

35

Zealand White rabbits Were used in this study, one eye

(control) received a polymethyl methacrylate intraocular
lens (IOL) (Chiron Intraoptics) While the other received an
IOL With codrug. Eyes Were examined regularly by slit lamp

40
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graphs of posterior capsule Were projected onto a grid and
the percentage of PCO calculated.
ERG and histopathologic data indicated that the codrugs
Were Well tolerated With no indication of a toxic or in?am

matory response. Slit lamp examination shoWed a statisti

mm incisions parallel to and 3 mm from the limbus. Animals
Were also examined by slit lamp and retinal function Was

assessed by electroretinogram (ERG) examination before
55

implantation and immediately before sacri?ce. Animals
Were periodically killed after implantation and eyes imme
diately enucleated and froZen. Vitreous Was then assayed for

This example indicates that codrug implants are Well

tolerated in the capsular bag. Signi?cantly, the development

5FU, THS and intact codrug by HPLC. Explanted devices

of PCO can be controlled over a prolonged period by the use

Were also assayed for residual drug.

of these implants.
60

EXAMPLE 8

Proliferative Vitreoretinopathy
To treat proliferative disorders in the vitreous or lens

Intravitreal Co-Delivery of TRI and 5FU
This example evaluates intravitreal co-delivery of 5FU
useful in the treatment of PVR.

Other Workers have reported that antimetabolites can also
inhibit neovasculariZation. Increased efficacy of THS may
be anticipated from the coadministration of 5FU. The inven
tors have developed a bioerodible implantable device by
preparing a 5FU/THS codrug. In vitro, devices release 2
moles of 5FU for each mole of THS.
2 mg codrug devices Were implanted into the vitreous of

20 NeW Zealand White rabbit eyes (ten animals) through 2.5

cally signi?cant decrease in PCO betWeen study and control
eyes (p<0.001). The less subjective assessment of PCO

and TRI in an animal model of proliferative vitreoretinopa
thy (PVR). Previous studies indicate that TRI and 5FU is

cornea models. Activity of this and related agents can be

acid, and cyclodextran.

mined by electroretinogram (ERG) before implantation and

using a grid con?rmed this observation and indicated an
arrest of opaci?cation in drug eyes With a statistical signi?
cance of p<0.03 by 8 Weeks.

steroid, and 5FU. THS has no corticosteroid activity but
inhibits neovaculariZation in the chick embryo and rabbit

enhanced by a variety of agents including aurin tricarboxylic

and PCO scored from 0 to 4+. Retinal function Was deter

before sacri?ce. Animals Were killed after 4, 8, 12 and 16
Weeks; eyes Were removed and ?xed in formalin. Photo

The example shoWs codrug technology as a means to

achieve the intravitreal delivery of 30., 17a, 21-trihydroxy
5B pregnane-20-one (THS), a model angiogenesis inhibiting

capsule such as proliferative vitreoretinopathy or posterior
65

capsular opaci?cation therapeutic concentrations of 5FU
(over 0.5 ug/ml) and corticosteroid (1 ug/ml) should be
maintained so as to at the same time inhibit ?broblast

proliferation (5FU inhibits groWth of ?broblasts) and pre

6,051,576
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vent in?ammation Which stimulates their proliferation (TRI

EXAMPLE 12

has potent anti-in?ammatory properties).

Codrug from Flurbiprofen and Acyclovir (See

Method to achieve sustained release of tWo or more

Scheme 2 BeloW)

Pharmacologically active compounds or codrugs from an

injectable formulation.

5

dicycloheXylcarbodiimide (DCC) and 13 mg of dimethy

A 10 mg/ml suspension of 5FU-TRI codrug Was prepared
in isotonic phosphate buffer. This Was injected into the
vitreous of 3 rabbits. One animal Was killed after 1, 3 and 7
days and both eyes Were removed. HPLC analysis Was
performed on each eye to detect intact codrug, TRI and 5FU.

10

tic levels of both 5FU and TRI in the vitreous over the 7 day

duration of this study.
15
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The compound is moreover relatively insoluble so that a
pellet can be compressed that does not dissolve in buffer at

pH 7.4. Such a pellet sloWly releases both TRI and 5FU over
an eXtended period of time (months) even When immersed in
pH 7.4. The advantage of such a system is that although each

25

of the parent compounds are released, the intact conjugate is
never detected in solution (its half-life is too short). This
conjugate can be formulated into a totally bio-erodible
sustained release system for 5FU and triamcinolone in the
eye. Both agents are presently used in combination and a

EXAMPLE 13

Codrugs from bis(hydroXymethyl)-5-?uorouracil and ?ur

biprofen (See scheme 3 beloW)

A 5FU/TRI codrug conjugate according to the invention
Was found to be unstable in buffer at pH 7.4, although it Was

stable in pH 3.0 (respective t1 /2 less than 15 minutes and
over 5 days).

laminopyridine (DMAP) Were miXed With 7 ml of dimeth
ylformamide. The miXture Was stirred at 55° C. overnight,
then evaporated to dryness under vacuum. The solid residue
Was chromatographed on silicagel to yield 340 mg of the

codrug (3a). 1H-NMR (DMSO), 6 1.4 (d, 2H CHZO), 3.8 (q,
1H CH), 4.1 (m, 2H), 5.3 (s,2H NCHZO), 6.5 (s, 2H NHZ),
7.15—7.55 (m,8H arom.), 7.8 (s, 1H CH).

Injection of the suspension Was found to maintain therapeu

EXAMPLE 10

200 mg of acyclovir, 160 mg of ?urbiprofen, 200 mg of

30

Flurbiprofen acid chloride (282 mg) Was dissolved in 3 ml
of acetonitrile. To this stirred solution triethylamine (142
mg) Was added folloWed by 5-?uorouracil (2) derivative
(170 mg). The cloudy miXture Was stirred at room tempera
ture overnight, diluted With dichloromethane, then Washed
With aqueous NaHCO3 solution, Water and brine. Chroma
tography on silica gel yielded 2 codrugs (4a). 145 mg of
monosubstituted product and 160 mg of bissubstituted prod
uct. 1H-NMR (acetone) for monoester, 6 1.7 (d,3H CH3), 3.9

(q, 1H CH), 5.75 (s,2H CHZN), 7.2—7.6 (m,8H arom.), 7.92
(d,1H). 1H-NMR (acetone) for diester, 6 1.5 (m, 6H 2CH3),
3.75 (m, 2H 2CH), 5.6 (s,2H CHZN), 6.0 (s, 2H CHZN),
7.0—7.6 (m,16H arom.).
EXAMPLE 14

sustained release form for one or the other has been a goal

of ophthalmologists for a long period.

Codrug from Prostaglandin PGFZOL and Timolol

In a similar Way a conjugate of 5FU and TRI can be used
as a codrug compound for the treatment of proliferative

vitreoretinopathy (PVR). A pellet of such an implant With
similar properties to the above is implanted intravitreally

35

carbonyldiimidaZole (35 mg) Was added and the resulting
solution Was stirred at 0° C. for 40 min. The solution of

after vitrectomy and is found to reduce the occurrence of
PVR. Animal studies are proceeding.

An additional manifestation of the codrug idea is the
conjugation of an anti-viral compound (ganciclovir or

acyclovir) With a nonsteroidal anti-in?ammatory agent
(?urbiprofen or indomethacin). These conjugates are
insoluble and Would be suitable for subconjunctival implan
tation in herpes keratitis.

102 mg of protected prostaglandin PGFZOL Was dissolved
in 4.5 ml of methylene chloride at 0° C. To this solution

timolol (54 mg) in 1 ml of methylene chloride Was then
40

added and the mixture Was heated at 50—54° C. overnight.
The solution Was Washed With Water and brine. Thus

obtained crude product Was puri?ed by chromatography and
redissolved in tetrahydrofuran (3 ml) at 0° C. To this stirred
solution tetrabutylammonium ?uoride Was added. After 0.5
h the solvent Was evaporated, the residue Was dissolved in
45

ethyl acetate, Washed With dil. sodium bicarbonate solution,
brine and dried over Na2SO4. The oily residue Was puri?ed

EXAMPLE 11
The folloWing is the structure of 5FU linked via a car
bonate bond to a glycerol di?urbiprofen ester. The rationale

is that the compound Would hydrolyZe in vivo to release
5FU, glycerol and tWo molecules of ?urbiprofen.

by preparative TLC to yield the eXpected codrug (39% of
yield). 1H-NMR (CDCl3), 6 0.85 (t, 3F CH3), 1.1 (s, 9H
t-Bu), 2.56 (d,2H CHZN), 3.5 (m,4H), 3.8 (m,4H), 3.9—4.2
(m,4H 3CHO+OH), 4.6 (m, 2H CHZO), 5.25 (m, 1H
CH—O), 5.3—5.6 (m, 4H ole?ne).
Synthesis Scheme

HO
COOH

1. TMS-Cl

2. timolol, DCC
DMAP
HO

OH
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EXAMPLE 15

30

Was achieved by treating the latter With 2.5 eq. of

monomethoxytrityl chloride in the presence of triethylamine

Codrug made of 5[3-pregnane-3ot, 170., 21-triol-20

and DMAP. The resulting ditrityl derivative 10 Was treated

one, ?urbiprofen and 5-?uorouracil (scheme 4)

With ?urbiprofen acid chloride to give the fully protected

1.4 ml of the solution of phosgene in toluene and 1 ml of

monoester 11. Removal of the trityl groups With acetic acid
35

the THF Were cooled to 0° C. in an ice-bath. To this stirred

provided the desired codrug 12.

mixture the solution of (5) (60 mg) and triethylamine (14.5

EXAMPLE 17

ML) in 1.5 ml of THF Was sloWly added. After 6 h the excess
of phosgene and the solvent Were removed in a stream of
nitrogen. The residue Was diluted With 1 ml of acetonitrile

Conjugates of 5-?uorouracil With ?urbiprofen,

and the solution of bis(hydroxymethyl) -5-?uorouracil (2)
(50 mg) and triethylamine (29 pL) in 1.5 ml of acetonitrile

40

Was added. The resulting homogenous solution Was kept in

refrigerator overnight. The residue obtained after solvent
evaporation Was puri?ed by preparative TLC yielding 52 mg
of the codrug
1H-NMR (CDCl3), 6 0.6 (s, 3H C-18), 0.9

resulted in compositions With improved properties.
45

obtained. If, hoWever, an oxygen atom is introduced at the

proximity of the hydroxyl group, the carbamate bond

EXAMPLE 16

becomes very labile. Via NMR, the inventors Were able to

Esters of acyclovir With ?urbiprofen and indomethacin

prove a carbamate bond Was formed. An attempt to prepare

the carbamate from 5FU and triamcinolone acetonide-21
chloroformate 1 failed completely. The inventors investi

have been synthesized as shoWn in Scheme 2 set forth

beloW, from the corresponding acids (activated With N,N
55

indomethacin Was used the amidoester 3b surprisingly Was
isolated from the reaction mixture.
60

be obtained by simple esteri?cation. HoWever, When the

used in all subsequent reactions Without further puri?cation.
coupled With 2 in acetonitrile in the presence of triethy

7 (via the intermediate diactetate), the acylation With excess

?urbiprofen, Scheme 6, required selective protection of one
of the tWo primary hydroxyl groups in ganciclovir 9. This

bis-(hydroxymethyl) derivative and ca. 35% of both the
isomeric mono-(hydroxymethyl) products. This mixture Was
Flurbiprofen and indomethacin acid chlorides Were

primary amino group Was protected as an N-trityl derivative

of indomethacin acid chloride gave the expected diester 8.
Synthesis of the monoester of ganciclovir With

gated the esteri?cation of the knoWn 1,3-bis
(hydroxymethyl)-5FU 2 With acid chlorides and
chloroformate. Compound 2 has been obtained from 5FU
and formalin as a viscous oil containing ca. 60% of the

The conjugate of ganciclovir and indomethacin has been
synthesiZed as presented in Scheme 5. This diester could not

5FU can be attached to hydroxy compounds as carbamate

(via the intermediate chloroformate) as shoWn in Scheme 7
beloW.
In the case of menthol 13, the stable product has been

(s,3H C19), 1.52 (d,3H CH3), 3.7 (q,1H CH), 4.75 (m,1H
C-3), 4.8—5.3 (2d,2H C-21), 5.7 (s,2H CHZN), 7.1—7.55
(m,8H arom.), 7.6 (d, 1H CH).

dicyclohexylcarbodiimide). Using this method the ester of
?urbiprofen 3a has been readily obtained, but When

indomethacin, and triamcinolone acetonide.
5FU remains a clinically important antiviral and antitu
mor agent, but it possesses high toxicity and far from
optimal delivery properties. Synthesis of a series of 5FU
conjugates With anti-in?ammatory drugs such as
?urbiprofen, indomethacin, and triamcinolone acetonide

lamine to give a mixture of the mono and diesters (Scheme
65

3).
In both cases the major product Was the 1-substituted
derivative and the separation of the mixture did not present

any dif?culty.

6,051,576
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An alternative approach involved the use of hydroxyesters

Was obtained as a minor side product. The acylation of 24

of ?urbiprofen to attach the 1,3-bis-(hydroxymethyl)-5FU
via a carbonate link (Schemes 8 and 9).
In the scheme 8 example, the monoester of ?urbiprofen

With ?urbiprofen acid chloride yielded the ester 25. For the

completion of the synthesis, the dihydroxyacetone side
chain Was liberated by treatment of 25 With hydro?uoric
acid in THF, and the resulting diol 5 Was chloroformylated

and triethylene glycol 13 Was prepared. the synthesis
required selective protection of one of the tWo hydroxyl
groups as a silyl derivative. Subsequent acylation and depro
tection led to the expected monoalcohol. This product Was
chloroformylated in THF With a solution of phosgene, and
coupled With 2 to yield the desired codrug 14.

and coupled With 2 to give the desired codrug 6.
The synthesis of the next series of codrugs is shoWn in
10

Alternatively, ?urbiprofen 1,3-diglyceride 15 Was

selective acylation of the 21-hydroxy group led to the
?urbiprofen ester 26. The benZyl group Was removed by
transfer hydrogenation and the resulting alcohol Was con

obtained by the methods of Scheme 9. In the ?rst approach,

dihydroxyacetone Was readily acylated With ?urbiprofen
acid chloride in the presence of pyridine, and the central keto
group Was rapidly reduced by sodium borohydride in THF

verted to the chloroformate 27. This product Was then
15

solution. Apuri?cation procedure using column chromatog
raphy on silica gel led to the expected monoalcohol 14.

The second approach involved the preparation of 1,3

subject to coupling With either 1,3-bis-(hydroxymethyl)
5FU, 2, or 5FU itself, Which gave the corresponding codrugs
28 and 29, respectively. Independently the tWo codrugs

containing only 5FU and 5[3-pregnane-3ot,17ot,21-triol-20

benZylidene glycerol, protection of the remaining hydroxyl

one Were prepared (Scheme 13).
The alcohol 24 Was hydrolyZed an(d chloroformylated to
the bis-chloroformate 30. When compound 30 Was coupled
With a 3 equivalents excess of 2, the expected codrug 31,
containing tWo 5FU residues, Was obtained. HoWever, if

group as an O-benZyl derivative, acidic hydrolysis of the

acetal and acylation of the diol With ?urbiprofen acid
chloride. Finally the benZyl group Was removed by transfer
hydrogenation in the presence of 10% Pd/C. Compound 15
Was chloroformylated and coupled With the 5-?uorouracil
derivative as described above, to yield the desired codrug

Scheme 12. The hydroxyl group of the alcohol 24 Was
protected as an O-benZyl derivative and then the bismeth
ylenedioxy group Was hydrolyZed in the usual fashion. The

25

16.
Triamcinolone acetonide Was bonded to the 1,3,-bis

only a 1.5 equivalents excess of 2 Was used, the monocar
bonate 32 Was isolated. The structure of 32 Was proven by

1H and 13C NMR analysis.
Due to the remarkable stability of ?urbiprofen esters at
pH 7.4, an alternative type of linear unit betWeen ?urbipro
fen and the steroidal alcohols Was considered (Scheme 14).

(hydroxymethyl)-5FU 2 via a carbonate (Scheme 1) linkage.
The product, obtained after the treatment of TRI With

phosgene, contained only one chlorformyl group. Steric
considerations make it practically impossible for the reac

In the reaction of chloroformate 33 With the salt of
?urbiprofen, it Was expected that a mixed anhydride of

tion to occur With the 11[3-hydroxyl group. The monochlo

roformate obtained above Was coupled With 2 to give the

?urbiprofen and carbonic acid Would be obtained. Instead,

expected crystalline codrug 17 after chromatographic puri

hoWever, the ester 34 Was isolated as the only product.

?cation.

35

Obviously, 34 is formed from the unstable, intermediate
mixed anhydride by elimination of carbon dioxide.

EXAMPLE 18

EXAMPLE 19

Codrugs Based on 5[3-Pregnane-3ot,17ot,21-Triol

Derivatives of AcetaZolamide

20-One.

AcetaZolamide is a useful drug for the treatment of

Triple codrugs composed of 3 components including an
antimetabolite agent (5FU), and anti-in?ammatory agent
(?urbiprofen) and an antivasculating agent (5[3-pregnane

3ot,17(x,21-triol-20-one).
Initially, tWo model compounds 19 and 20 (Schemes 10
and 11) Were synthesiZed and evaluated With respect to the

glaucoma. HoWever, due to its unfavorable lipophilicity it is
not active When given topically to the eye. Approaches to
solve the delivery problems may include the development of
45

appropriate codrug forms. Preparation of sulfocarbamate
derivatives of acetaZolamide are shoWn in Scheme 15. The
product 35 appears to stable in buffer solution to ensure a
sufficient rate and extent of codrug conversion to the parent

stability in aqueous solution as a function of pH.

drug at this time.

The easily available 5[3-androgen-3ot-ol-17-one (18) Was
acylated With ?urbiprofen acid chloride in pyridine in the

EXAMPLE 20

presence of DMAP. The resulting ketoester 19 Was then

reduced in high yield to the alcohol 20. For the completion
of the synthesis, the alcohol Was chloroformylated in the
usual fashion, and coupled With 5FU to yield the expected

product 21.

The folloWing example relates to a method for making
and using a suramin and amiloride codrug as a means to
55

esis and cancer.

In the second synthesis model, the simple ester 22 of

?urbiprofen and 5[3-pregnane-3ot,17ot,21-triol-3,20-dione

Speci?cally, Vassalli and Belin, FEBS Letters,
“Amiloride Selectively Inhibits the Urokinase-type Plasmi
nogen Activator” Volume 214, Number 1, p. 187—191 (April
1987), describe the selective inhibition of urokinase-type
plasminogen activator by amiloride in cell culture. Kellen et

Was obtained as shoWn in Scheme 11. Synthesis of all

“triple” codrugs have been based on the easily available and

relatively cheap Reichstein’s Substance 23 (Scheme 4). This
material Was transformed in the usual Way (formalin and

concentrated HCl in methylene chloride) to its bismethyl
enedioxy derivative, Which Was then hydrogenated in high
yield With palladium-on-calcium carbonate in the presence
of potassium hydroxide, to the saturated 5[3-pregnanone.

inhibit angiogenesis. It is Well settled that individually both
suramin and amiloride are potential therapies for angiogen

al., “Antimetastatic Effect of Amiloride in an Animal

Tumour Model”, Anticancer Res., Volume 8, p. 1373—1376
65

(1988) shoW that amiloride exerts an anti-metastatic effect in
a rat model. The anti-angiogenic effects of amiloride have

This ketone Was then reduced With sodium borohydride,

been demonstrated in the embryonic egg model (CAM

predominantly to the equatorial alcohol 24; the axial alcohol

assay) by Chen et al., Investigative Ophthalmology and

6,051,576
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Visual Science, Vol. 35, No. 4, Abstract 1157-28, Mar. 15,

amount to inhibit angiogenesis of a codrug of suramin
ionically linked to amiloride to a patient in need of angio

1994. The same authors have presented data showing a
bene?cial effect of systemically administered amiloride on
subretinal neovasculariZation in man (Chen et al., Investi

genesis inhibition.
Effective dosages of suramin-amiloride codrug are in the

gative Ophthalmology and Visual Science, Vol. 35, No. 4, 5 range of about 1—30 mg/kg body Weight and preferably from
Abstract 1171-42, Mar. 15, 1994).
about 10—20 mg/kg body Weight.. The suramin/amiloride
codrug is preferably formulated into a sustained release
Suramin, Which inhibits various groWth factors, has been
shoWn to retard Wound healing When applied in a liposomal
pellet comprising about 1/2 gram of codrug. The suramin/
amiloride codrug may be formulated for ophthalmic use to
form (Butler et al., Investigative Ophthalmology and Visual
achieve an effective concentration in the eye of 5 mcg/ml of
Science, Vol. 35, No. 4, Abstract 829-86, Mar. 15, 1994).
codrug components, in a liquid formulation. In the
Collins et al., “Inhibition of Angiogenesis by Suramin”,
alternative, the codrug may be administered intra-arterially
Cancer Research, Volume 52, p. 5073—5075 (Sep. 15, 1992)
for the treatment of Kaposi’s sarcoma. The suramin/
and Hassan et al., Investigative Ophthalmology and Visual
amiloride codrug may be administered by injection for the
Science, Vol. 35, No. 4, Abstract 566-14, Mar. 15, 1994),
have also shoWn suramin to be a potent inhibitor of angio

15 treatment of arthritis.

genesis in the Chick Chorioallantoic Membrane (CAM)
assay. See also Abstracts 417, Amiloride; and 8696, Suramin
Merck Index, 11th Ed., Merck and Co., Inc. (1989) and
references cited therein, incorporated by reference herein in
its entirety.

EXAMPLE 21

Codrug from Ethacrynic Acid and Atenolol
Ethacrynic acid is a diuretic and atenolol is an antihyper
tensive drug. They may be formulated into a codrug as
folloWs. 200 mg of ethacrynic acid Was dissolved in 4 mL of

The chemical structures of amiloride and suramin are set

forth beloW.

c1
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\
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NH
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HZN
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NHZ
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NaO3S

HNOC

CONH

503“

SO3Na

CH3 (ED/M1035
NH

NH

CO

CO

NaO3S

SO3Na

% NHCONH %
Suramin Sodium

These reports shoW that although both suramin and 50 anhydrous dichloromethane and to this stirred solution at
amiloride individually inhibit angiogenesis, their mode of
room temperature 128 mg of DCC Was added folloWed by
action is different. Thus, the tWo agents administered linked
10 mg of dimethylaminopyridine (DMAP) and 128 mg of
together by ionic bonding as a codrug appear to have a

atenolol. The resulting mixture Was stirred at room tempera

synergistic effect.

ture overnight, diluted With 30 mL of dichloromethane,
Washed With sodium bicarbonate solution, Water and brine.
The residue after solvent evaporation Was chromatographed
on silicagel to yield 62 mg of the expected codrug. 1H-NMR

Amiloride is available from Sigma Chemical Co., St.
Louis Mo. and Suramin is available from Mobay Chemical
Co, NeW York, NY. The tWo drugs are ionically linked to
one another via an ionic bond to form a single codrug salt

compound.
The tWo drugs may be ionically linked by mixing solu
tions of the tWo compounds. Amiloride is dissolved in Water
to form a saturated solution. Suramin is added to the

amiloride solution and suramin/amiloride salt forms. Six
amiloride molecules ionically bond to each single suramin
molecule. The precipitate is collected.

A method of inhibiting angiogenesis according to the
present invention comprises administering an effective

60

(CDCl3) 6 1.14 (t, 3H), 1.26 (d, 3H), 1.31 (d, 3H), 2.46 (q,
2H), 3.50 (s, 2H), 3.52 (m, 1H), 4.25 (m, 1H), 4.91 (2d, 2H),
5.60 (s, 1H), 5.94 (s, 1H), 7.12—7.28 (m, 6H). See synthesis
sheme 16 beloW.
EXAMPLE 22

Codrug from THS, 5-FU and Diethylene Glycol
3ot,17ot-21-trihydroxy-5[3 pregnane-20-one (THS) can be
formulated in to a codrug With 5FU and diethylene glycol to

6,051,576
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form an angiostatic steroid. A biscarbonate of THS and

23.1 (019), 14.6 (C-18) ppm. 16 1H-NMR(CDC13) 6 0.66

diethylene glycol (75.3 mg) Was chloroformylated With

(s, 3H, C-18), 0.94 (s, 3H, c-19), 3.61—3.79 (m, 14H,
OCHZ-PEG), 4.30—4.34 (m, 2H, ocoocnz), 4.64 (m, 1H,
03), 4.98 (dd, 2H, c-21), 5.65 (s, 2H, OCHZN), 7.62 (01,
C6‘), E.70 (1H, NH) ppm; 13c-NMR (CDC13) 6 204.5
(020), 156.2 (d, c-4‘), 154.9, 154.2 (2><ocoo), 148.7
(c-2‘), 140.1 (d, C-F), 128.1 (d, C-6‘), 90.2 (017), 80.0
(03), 72.3 (OCOOQH2) 71.4 (OCHZN), 67.6 (CHZOH),

phosgene in tetrahydrofuran in the presence of triethy
lamine. Thus obtained bischloroformate Was dissolved in

dry acetonitrile and conjugated With bishydroXymethyl-5
?uorouracil. The column chromatography on silicagel
afforded 95 mg of codrug (79% yield) as a White solid foam.

1H-NMR (CDCl3) 6 0.64 (s, 3H, C-18), 0.92 (s, 3H, C-19),
3.73 (m, 8H, PEG), 4.22—4.38 (m, 8H, PEG), 4.59 (m, 1H,
C-3), 5.20 (dd, 2H, C-21), 5.70 (m, 4H, 2><OCH2N), 7.68,
7.70 (2d, 2><CH=CF), 9.72, 9.83 (2d, 2H, NH) ppm;
13C-NMR (CDCl3) 6 205.0 (C-20), 157.2, 156.9 (2d, 2><C
4‘), 154.9, 154.7, 154.6, 154.5 (4><OCOO), 149.3, 149.2
(2><C-2‘), 140.2 (d, C-F), 128.4 (d, C-6‘), 90.4 (C-17), 78.3
(C-3), 23.1 (C-19), 14.7 (C-18) ppm. See synthesis sheme 17

23.1 (C-19), 14.7 (C-18) ppm. See synthesis sheme 18
10

EXAMPLE 24

Codrug from PG-Fza Triacetate and Timolol
15

Prostaglandin E2 alpha (PGF2ot) can be formulated into a
codrug With timolol (TM) as set forth beloW. PG-Fza triac
etate (95.4 mg) Was dissolved in 3 mL of dry dichlo
romethane and DCC (41.2 mg) Was added folloWed by
dimethylaminopyridine (10 mg). The mixture Was stirred at

20

room temperature for 15 min. and the solution of timolol

beloW.
EXAMPLE 23

Codrugs from THS, 5FU and Tetraethylene Glycol

(119.6 mg) in 1 mL of dichloromethane Was added.

3ot,17ot-21-trihydroXy-5[3 pregnane-20-one (THS) can be
formulated in to a codrug With 5FU and tetraethylene glycol
to form an angiostatic steroid. 112.9 mg of the prodrug
prepared from THS and tetraethylene glycol Was dissolved
in 3 mL of dry THF and triethylamine (55 pL) Was added

The resulting mixture Was stirred at room temperature

overnight, ?ltered, diluted With dichloromethane, Washed
With Water, brine and ?nally dried over sodium sulfate. The
25

residue after solvent evaporation Was separated by column

chromatography affording the codrug (61.3 mg, 39.7%

folloWed by the solution of phosgene (2.81 mL). The miX

yield) as an oil. 1H-NMR (CDCl3), 6 0.88 (t, 3H), 1.07 (s,

ture Was stirred at room temperature overnight, evaporated

to dryness, redissolved in dry acetonitrile (2 mL) and added
to the stirred solution of bishydroXymethyl-5-?uorouracil

(150 mg) and triethylamine (66.3 pL) in acetonitrile (5 mL).

beloW.

30

After 14 hours at room temperature the products Were

9H), 1.24—1.7 (m, 14H), 2.02 (s, 3H), 2.04 (s, 3H), 2.05 (s,
3H), 2.30 (m, 2H), 2.54 (m, 2H), 2.80 (d, 2H), 3.50 (m, 4H),
3.78 (t, 4H), 4.58 (m, 2H), 4.88 (m, 1H), 5.08 (t, 1H), 5.23
(m, 2H), 5.34 (m, 2H), 5.53 (m, 2H) ppm. See synthesis

isolated and puri?ed by column chromatography affording

sheme 19 beloW.

the tWo codrugs: more polar 15 (129.3 mg, 69% yield) and
less polar 16 (20.7 mg, 14% yield), both as White solid

Dosages may be calculated by those of skill in the art in
accordance With methods set forth in Goodman and Gilman,

foams. 15 1H-NMR (CDCl3) 6 0.62 (s, 3H, C-18), 0.95 (s,
3H, C-19), 3.64—3.78 (m, 12H, PEG), 4.29—4.37 (m, 4H,
2><OCOOCH2), 4.63 (m, 1H, C-3), 5.00(dd, 2H, C-21), 5.65,
5.67 (2s, 4H, 2><NCH O), 7.65 (2d, 2H, CH=CF), 9.25,
9.35 (2><NH) ppm; 1 C-NMR (CDCl3) 6 205.0 (C-20),

154.9, 154.6, 154.1 (3><OCOO), 90.1 (C-17), 80.0 (C-3),
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The Pharmacological Basis of Therapeutics, 8th Ed., Per
gamon Press, NY, 1990; and The Merck Index, 11th Ed.,
Merck and Co., Inc., Rahway, NJ. 1989; incorporated herein
by reference in their entireties. Dosages are preferably in the
range of about 1 to about 500 mg/kg body Weight, and are
administered preferably 1 to 2 times a day.

SCHEME 1

